Capstone Holding director discloses indirect stake
Capstone Holding Corp. director Michael Toporek reports his initial beneficial ownership, consisting entirely of indirect holdings.
Rhea-AI Filing Summary
Capstone Holding Corp. director Michael Toporek reports his initial beneficial ownership, consisting entirely of indirect holdings. As of February 14, 2025, he controls 121,774 shares of Common Stock through BP Peptides, LLC and related entities, and an indirect warrant to purchase up to 6,322 shares of Common Stock at an exercise price of $75.00 per share, expiring on October 15, 2028. The warrant is held by Brookstone Partners IAC, Inc., investment manager to BP Peptides, LLC, which is controlled by Matthew Lipman and Michael Toporek.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
TOPOREK MICHAEL
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock Warrants F2 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Common Stock Warrants — 6,322 contracts (Indirect, See footnote);
Common Stock — 121,774 shares (Indirect, See footnote)
Footnotes (2)
- F1. Consists of 121,774 shares controlled by Michael Toporek, through his control of BP Peptides, LLC. Brookstone Acquisition Partners XXI Corporation owns 81% of BP Peptides, LLC. Mr. Toporek owns approximately 30% of Brookstone Acquisition Partners XXI Corporation.
- F2. Includes a warrant to purchase up to 6,322 shares of Common Stock issued to Brookstone Partners IAC, Inc., the investment manager of BP Peptides, LLC which is controlled by Matthew Lipman and Michael Toporek.
Key Figures
Indirect Common Stock holdings: 121,774 shares
Warrant underlying shares: 6,322 shares
Warrant exercise price: $75.0000 per share
+1 more
4 metrics
Indirect Common Stock holdings
121,774 shares
Shares of Capstone Holding Corp. Common Stock controlled indirectly by Michael Toporek via BP Peptides, LLC
Warrant underlying shares
6,322 shares
Underlying Common Stock shares for warrant held indirectly through Brookstone Partners IAC, Inc.
Warrant exercise price
$75.0000 per share
Exercise price of Common Stock Warrant expiring October 15, 2028
Warrant expiration date
2028-10-15
Expiration date of indirect Common Stock Warrant for 6,322 underlying shares
Key Terms
indirect beneficial ownership, Common Stock Warrants, exercise price, investment manager
4 terms
indirect beneficial ownership financial
"All reported positions are indirect beneficial ownership held through entities"
Common Stock Warrants financial
"Includes a warrant to purchase up to 6,322 shares of Common Stock"
Common stock warrants are tradable certificates that give the holder the right, but not the obligation, to buy a company’s common shares at a fixed price before a specified expiration date. They work like long-term options issued by the company and can provide cheaper, leveraged exposure to a stock’s potential upside; however, if holders use the warrants to buy shares, the total number of shares increases, which can dilute the value of existing shares.
exercise price financial
"an indirect warrant to purchase up to 6,322 shares at an exercise price of $75.00"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
investment manager financial
"warrant issued to Brookstone Partners IAC, Inc., the investment manager of BP Peptides, LLC"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Capstone Holding Corp. (CAPS) director Michael Toporek report in this Form 3?
Director Michael Toporek reports only indirect beneficial ownership. He controls 121,774 Common Stock shares via BP Peptides, LLC and related entities, plus an indirect warrant for 6,322 underlying shares at a $75.00 exercise price, expiring October 15, 2028.
Through which entities are Michael Toporek’s CAPS holdings structured?
The 121,774 shares are controlled via BP Peptides, LLC, 81% owned by Brookstone Acquisition Partners XXI Corporation, of which Toporek owns about 30%. The 6,322-share warrant is issued to Brookstone Partners IAC, Inc., investment manager to BP Peptides, LLC.
Are Michael Toporek’s reported CAPS holdings direct or indirect?
All reported positions are indirect. Both the 121,774 Common Stock shares and the warrant for 6,322 underlying shares are held through entities such as BP Peptides, LLC and Brookstone Partners IAC, Inc., rather than in Toporek’s own name directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
